--赛诺菲公司的疫苗生产部门在最近18个月一直饱受召回和疫苗短缺的困扰。在即将到来的九月份原本是其疫苗产品生产重新恢复正常的日子，然而由于一项检测结果异常，赛诺菲恐将这一日期拖后至十月中旬。这次的检测问题主要涉及Daptacel和Pentacel两种疫苗。在赛诺菲无法正常提供疫苗的这段时间，将由默沙东和葛兰素史克两家来弥补这一疫苗缺口。

详细英文报道：

Sanofi's ($SNY) vaccine manufacturing plants have had a rocky 18 months, with warning letters, recalls and shortages marring 2012. Next month was supposed to be a milestone in efforts to resume full supply of all vaccines, but now a testing anomaly has caused further delays.

The problem this time relates to a filling line at the plant that manufactures two combination vaccines, Daptacel and Pentacel. Sanofi began limiting orders of the vaccines--which protect against diphtheria, tetanus, pertussis (DTaP), polio and Haemophilus influenzae type B--in April 2012. Three months ago, Sanofi pencilled in the start of September for a return to full production, but it is now set to miss this target.

As well as delaying the return of Daptacel and Pentacel to mid-October, Sanofi is now struggling to meet demand for another two products, the Adacel vaccine and Tubersol diagnostic antigen. Both were affected by the same problem that delayed the return of Daptacel and Pentacel, AAFP News Now reports. "This delay resulted from an anomaly identified during a routine test procedure of one of our filling lines, and, since a repeat test is now required, all products from that line are delayed," Sanofi's vice president of U.S. marketing, William Averbeck, said during a teleconference with the Centers for Disease Control and Prevention (CDC) and various health organizations.

While Sanofi resolves the delay--which is unrelated to process improvements it is making at the plant--GlaxoSmithKline ($GSK) and Merck ($MRK) will cover the shortfall in supply with their rival vaccines. CDC will also dip into the Strategic National Stockpile to ensure that enough doses are available.